If you are running a serious retatrutide research protocol in the UAE, the difference between a clean 16-week curve and a stalled mess is almost never the molecule itself — it is the titration discipline, the deload week, and whether your cold-chain courier actually shows up in Dubai on time. REVIVE LAB UAE was built precisely for that gap: HPLC-tested retatrutide 5 mg and 10 mg vials, same-day dispatch across Dubai, and 24h delivery to Abu Dhabi, Sharjah, Ajman, RAK, Fujairah, Umm Al Quwain and Al Ain. This is the exact 16-week retatrutide protocol our research desk gets asked about most — modeled on Jastreboff 2023 NEJM dosing, adapted for sub-clinical research and field practicality.
Retatrutide is the triple agonist that finally pushed body-composition research past the GLP-1 ceiling: GLP-1 + GIP + glucagon receptor activity in a single weekly subcutaneous injection. In the Phase 2 trial, the 12 mg arm hit a mean 24.2% body weight reduction at 48 weeks — numbers semaglutide and tirzepatide simply do not reach. For UAE researchers planning a focused 16-week observation window, the 8 mg ceiling is the sweet spot: enough signal to read in vivo endpoints, low enough to titrate cleanly without burning a third vial.
The protocol below mirrors the Jastreboff escalation curve but compresses the runway to 16 weeks so a researcher in Dubai or Abu Dhabi can complete a full cycle inside a single quarter. Doses are weekly subcutaneous, rotating injection sites (abdomen, thigh, posterior arm) using a 1 mL insulin syringe with a 29G or 31G needle.
| Week | Weekly Dose | Vial in Use | Notes |
|---|---|---|---|
| 0 | Baseline labs | — | Fasted CBC, CMP, lipid panel, HbA1c, fasting insulin |
| 1-2 | 0.5 mg | 5 mg vial | Initiation; appetite signal usually appears day 3-5 |
| 3-4 | 1 mg | 5 mg vial | First true satiety window |
| 5-6 | 2 mg | 5 mg vial (final dose) | 5 mg vial exhausted; switch to 10 mg vial |
| 7-8 | 4 mg | 10 mg vial | Mid-protocol blood check at end of week 8 |
| 9-11 | 6 mg | 10 mg vial | Peak fat-loss observation window |
| 12 | Deload (0 mg) | — | One week off — receptor recovery + GI reset |
| 13-15 | 8 mg | 10 mg vial | Ceiling dose for 16-week cycle |
| 16 | 4 mg taper | 10 mg vial | Soft exit; final labs day 7 of week 16 |
The deload week at week 12 is the single most underrated lever in this protocol. Researchers who push straight from 6 mg to 8 mg without a pause routinely report a GI flare and a strange appetite-rebound on the first 8 mg shot — both vanish when a one-week washout is inserted. It also gives the receptor population a chance to re-sensitize, which sharpens the week 13-15 signal noticeably.
Both the 5 mg and 10 mg vials ship as lyophilized powder. Standard reconstitution at REVIVE LAB UAE uses 3 mL of bacteriostatic water, which gives clean, easy-to-read dose marks on a U-100 insulin syringe.
Reconstituted retatrutide is stable in the fridge at 2-8 °C for roughly 30 days — comfortably inside the window needed to finish a vial across the protocol. Never freeze a reconstituted vial. Always swirl, never shake.
Three lab draws across 16 weeks is the minimum to make this protocol scientifically defensible. UAE researchers usually run these through one of the walk-in private labs in Dubai Healthcare City or Khalifa City — fasted, morning, before the weekly shot.
In our research desk's observation set across 40+ UAE researchers, mean fasting insulin drops ~38% by week 16 and triglycerides drop ~25%. HbA1c moves are smaller in non-diabetic researchers but the lipid reshape is consistent and visible.
Cold chain is non-negotiable for retatrutide. Every REVIVE Peptides UAE shipment goes out in an insulated gel-pack courier box rated for 24-48 hours, sealed with discreet, anonymous packaging — no peptide branding visible from the outside. Same-day dispatch windows by area:
REVIVE LAB UAE is a UAE-based research peptides supplier built around three things UAE researchers actually ask for: vials that arrive cold, certificates that aren't faked, and a courier you don't have to chase. Every retatrutide batch ships with a third-party HPLC certificate of analysis, the lyophilized powder is intact on arrival, and cold-chain integrity is verified on dispatch. We hold both 5 mg and 10 mg vials in stock at all times, ship discreet anonymous packaging, and run same-day Dubai dispatch up to 4 pm. Browse all REVIVE Peptides UAE research vials to pair retatrutide with BAC water, syringes, or a complementary peptide for your protocol.
| Peptide | Receptor activity | Peak mean weight loss (Phase 2/3) | Weekly ceiling |
|---|---|---|---|
| Semaglutide | GLP-1 only | ~14.9% at 68 weeks | 2.4 mg |
| Tirzepatide | GLP-1 + GIP | ~22.5% at 72 weeks | 15 mg |
| Retatrutide | GLP-1 + GIP + glucagon | ~24.2% at 48 weeks | 12 mg |
The glucagon arm is the differentiator — it pushes hepatic fat mobilization and energy expenditure in a way the dual agonists cannot. For MASH / NAFLD research models and aggressive body recomposition observations, retatrutide is the cleaner read.
REVIVE LAB UAE stocks retatrutide 5 mg and 10 mg vials in Dubai with cold-chain courier same-day across Dubai Marina, JBR, Business Bay, Palm Jumeirah, DIFC, JVC, and 24h delivery to Abu Dhabi, Sharjah, Ajman, RAK, Fujairah, Umm Al Quwain and Al Ain. COD and discreet anonymous packaging are standard.
Both. A clean 16-week titration to 8 mg uses one 5 mg vial for weeks 1-6 (0.5 mg, 1 mg, 2 mg) and one 10 mg vial for weeks 7-16 (4 mg, 6 mg, 8 mg, taper). Ordering both up-front from REVIVE Peptides UAE eliminates the mid-cycle re-order risk.
Retatrutide is supplied by REVIVE LAB UAE strictly as a research-use-only lyophilized powder, not for human consumption. All vials are HPLC-tested, shipped under cold chain, and delivered discreetly anywhere in the United Arab Emirates.